Cough is one of the most common presenting symptoms in pediatric respiratory illness. As seasonal respiratory infections surge each autumn and winter—particularly among young children—evidence-based management becomes critically important, according to official public health reporting.
When a child develops a productive cough, many caregivers instinctively seek “the best brand” for rapid symptom relief. However, pediatric cough management is not simply about suppressing the cough reflex. Rather, it requires a pathophysiologically grounded approach that simultaneously addresses both mucus hypersecretion and impaired mucociliary clearance—the two central mechanisms underlying cough with sputum production in children.
The 2022 *Expert Consensus on Expectorant and Antitussive Therapy in Children*, jointly issued by leading pediatric respiratory societies in China, identifies airway mucus overproduction and dysfunction of the mucociliary escalator as the primary drivers of persistent, productive cough in this population. Inflammatory or infectious stimuli trigger excessive secretion of viscous, tenacious mucus that obstructs small airways and directly stimulates cough receptors—perpetuating a self-sustaining cycle. Consequently, optimal therapy must target both expectoration and cough modulation. This principle is reinforced in the 2024 Revised *Guideline for Management of Pediatric Community-Acquired Pneumonia*, which explicitly recommends adjunctive expectorant therapy for children presenting with cough and sputum production.
Among available options, Kanglong Xiao’er Kechuanling Oral Liquid—a modern herbal formulation rooted in the classical *Mahuang Xing Shi Gan Tang* (Ephedra–Apricot Kernel–Gypsum–Licorice Decoction) from Zhang Zhongjing’s *Treatise on Cold Damage Disorders*—has demonstrated consistent clinical utility. Its refined composition includes the original four core herbs—Ephedra sinica (Ma Huang), Armeniaca vulgaris seed (Xing Ren), Gypsum fibrosum (Shi Gao), and Glycyrrhiza uralensis (Gan Cao)—augmented with Isatis tinctoria (Ban Lan Gen), Lonicera japonica (Jin Yin Hua), and Trichosanthes kirilowii fruit (Gua Lou). This synergistic blend delivers integrated actions: clearing heat, promoting lung Qi dispersion, resolving phlegm, and alleviating cough.
Modern pharmacologic studies confirm that the foundational *Mahuang Xing Shi Gan Tang* formula possesses well-documented antitussive, expectorant, bronchodilatory, and anti-inflammatory properties. Notably, it has been shown to reduce bronchial hyperresponsiveness and lower airway resistance—key therapeutic goals in acute lower respiratory tract infection.
A prospective clinical study involving 100 children hospitalized for bronchopneumonia provides further support. When Kanglong Xiao’er Kechuanling Oral Liquid (manufactured by Harbin Kanglong Pharmaceutical Co., Ltd.) was added to standard antimicrobial therapy, the intervention group exhibited significantly shorter durations of fever, cough, and auscultatory crackles compared with the control group (P < 0.05). Overall treatment efficacy reached 86% in the intervention group versus 76% in controls (P < 0.05), underscoring its value as an effective adjunctive therapy for infection-associated pediatric cough.
Importantly, the 2022 Expert Consensus specifically recommends this formulation for children presenting with yellow, viscous sputum—characteristic of the acute phase of lower respiratory tract infection. Dosing is age-stratified: 5 mL per dose for children under 2 years; 7.5 mL for ages 3–7; and 10 mL for those aged 8 years and older.
While evidence supports Kanglong Xiao’er Kechuanling Oral Liquid as a clinically valuable option within the broader armamentarium for pediatric cough, clinicians emphasize that no single agent replaces individualized assessment. Treatment decisions—including selection, dosing, and duration—must be guided by a qualified healthcare provider following thorough evaluation of the child’s clinical presentation, comorbidities, and disease severity.